Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_assertion type Assertion NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_head.
- NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_assertion description "[We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_provenance.
- NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_assertion evidence source_evidence_literature NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_provenance.
- NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_assertion SIO_000772 12640257 NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_provenance.
- NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_assertion wasDerivedFrom befree-20140225 NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_provenance.
- NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_assertion wasGeneratedBy ECO_0000203 NP302722.RAaGFfhszgwVdn6E86plhYxY8kitLce7OvFUNJh0Q26cE130_provenance.